Patents Examined by Jegatheesan Seharaseyon
  • Variant type III interferons and synthekines
    Patent number: 11198717
    Abstract: Compositions and methods are provided relating to Type III interferons.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: December 14, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Juan Luis Mendoza, Kenan Christopher Garcia
  • Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of GDF-15, natriuretic peptide, cardiac troponin or combinations thereof
    Patent number: 11199552
    Abstract: The present invention relates to a method of identifying a subject being susceptible to a cardiac intervention based on the determination of GDF-15 in a sample of a subject in need of a cardiac intervention. Moreover, the present invention pertains to a method for predicting the risk of mortality or a further acute cardiovascular event for a subject suffering from a cardiovascular complication based on the determination of GDF-15 and a natriuretic peptide and/or a cardiac troponin in a sample the said subject. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: December 14, 2021
    Assignee: MEDIZINISCHEN HOCHSCHULE HANNOVER
    Inventors: Kai C. Wollert, Tibor Kempf, Lars Wallentin, Helmut Drexler
  • TGFbeta 2 antibodies
    Patent number: 11180546
    Abstract: This invention is in the field of anti-transforming growth factor beta 2 (TGF-?2) antibodies. In particular, the invention provides human monoclonal antibodies that bind the human TGF-?2 isoform preferentially over the human TGF-?1 or TGF-?3 isoforms.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: November 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Chikwendu Ibebunjo, Carsten Jacobi, Angelika Meyer, Eveline Schaadt, Anne-Ulrike Trendelenburg, Olga Vladimirovna Mitina
  • Type I interferon receptor antibody and use thereof
    Patent number: 11136399
    Abstract: The present disclosure discloses monoclonal antibodies binding to type I interferon alpha receptor and their uses. The antibodies are capable of inhibiting the biological activity of type I interferons, and can be used for treating, preventing, or diagnosing the diseases mediated by the type I interferons. Also provided are immunoconjugate, bispecific molecule and pharmaceutical compositions comprising the antibodies of the present disclosure.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: October 5, 2021
    Assignee: INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES
    Inventors: Liguo Zhang, Lishan Su, Jingyun Li, Jianping Ma
  • Anti-IL-5 antibodies
    Patent number: 11111292
    Abstract: Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: September 7, 2021
    Assignee: CEPHALON, INC.
    Inventors: Mark Terence Liddament, Anthony Doyle, Adam Clarke, David Jose Simon Laine, Bridget Ann Cooksey
  • Anti-canine TARC antibody used for treatment and diagnosis of canine atopic dermatitis
    Patent number: 11104727
    Abstract: Provided are an anti-canine TARC antibody for use in the treatment and diagnosis of canine atopic dermatitis, and a method for treating or diagnosing canine atopic dermatitis using the same. An anti-canine TARC monoclonal antibody binding to canine TARC, comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 4, or a functional fragment thereof binding to canine TARC.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 31, 2021
    Assignee: NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Toshihiro Tsukui, Miyuki Kageyama, Masahiro Kato, Rieko Suzuki
  • Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
    Patent number: 11091543
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 17, 2021
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • IL-11R? antibodies
    Patent number: 11084878
    Abstract: Provided are antigen-binding molecules capable of binding to IL-11R?, and methods of medical treatment and prophylaxis using the same.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 10, 2021
    Assignees: National University of Singapore, Singapore Health Services PTE LTD., Boehringer Ingelheim International GmbH
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Targeted mutant interferon-gamma and uses thereof
    Patent number: 11084859
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 10, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman, Lennart Zabeau
  • IL-11 antibodies
    Patent number: 11084874
    Abstract: Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 10, 2021
    Assignees: Singapore Health Services PTE LTD., National University of Singapore, Boehringer Ingelheim International GmbH
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • IL-11 antibodies
    Patent number: 11078268
    Abstract: IL-11 antibodies are disclosed. Also disclosed are compositions comprising the IL-11 antibodies, and methods using the IL-11 antibodies.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 3, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Biological marker for evaluating the IL-17 pro-inflammatory functional contribution dependent level in an individual
    Patent number: 11079391
    Abstract: The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 3, 2021
    Assignees: Hospices Civils de Lyon, Universite Claude Bernard Lyon 1
    Inventors: Pierre Miossec, Ndieme Thiam
  • Cancer treatment
    Patent number: 11078289
    Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: August 3, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • CD80 variant immunomodulatory proteins and uses thereof
    Patent number: 11078282
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 3, 2021
    Assignee: ALPINE IMMUNE SCIENCES, INC.
    Inventors: Ryan Swanson, Michael Kornacker
  • IL-11R? antibodies
    Patent number: 11078269
    Abstract: IL-11R? antibodies are disclosed. Also disclosed are compositions comprising the IL-11R? antibodies, and methods using the IL-11R? antibodies.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 3, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Anti-human IL-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of IL-3, and their use in a method to detect human IL-3
    Patent number: 11078266
    Abstract: Anti-human interleukin 3 (IL-3) antibodies or fragments thereof according to the present invention are useful as therapeutic agents. The antibodies can be used in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated expression or levels of human IL-3 in a patient, especially inflammatory or autoimmune diseases, such as rheumatoid arthritis. The antibodies can also be used to detect human IL-3 expressed by human cells.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: August 3, 2021
    Assignee: Universitätsklinikum Regensburg
    Inventors: Matthias Mack, Hilke Bruhl, Kerstin Renner
  • Interferon receptor 1 antibodies and their uses
    Patent number: 11072664
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 27, 2021
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • Anti-IFNAR1 antibodies for treating autoimmune diseases
    Patent number: 11059897
    Abstract: Provided are antibodies or fragments thereof having binding specificity to the human interferon alpha and beta receptor subunit 1 (IFNAR1) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as provided, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: July 13, 2021
    Assignee: I-Mab Biopharma US Limited
    Inventors: Wei Cao, Weili Xu
  • IL-12 P40 monomer, monoclonal antibody against P40 homodimer and the combination of the two for autoimmune disease treatment
    Patent number: 11045545
    Abstract: A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p402), and the IL-23. To facilitate the studies on p402 and p40, neutralizing monoclonal antibodies (mAb) against mouse p402 and p40 were generated for the first time. MS and other autoimmune disease drug therapies including recombinant p40 and/or monoclonal antibody against p402 (mAb-p402 a3-1d) are disclosed.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: June 29, 2021
    Assignee: Rush University Medical Center
    Inventor: Kalipada Pahan
  • Humanized anti clever-1 antibodies and their use
    Patent number: 11046761
    Abstract: This invention relates to an agent and a humanized antibody or single chain Fv or Fab fragment capable of binding to human CLEVER-1 recognizing an epitope of CLEVER-1, wherein the epitope is discontinuous and comprises the sequences: PFTVLVPSVSSFSSR and QEITVTFNQFTK. This invention relates also an agent capable of binding to an epitope of human CLEVER-1 for use in removing tumour or antigen induced immunosuppression. Further, the invention relates to a pharmaceutical composition comprising the agent capable of binding to human CLEVER-1 and an appropriate excipient.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: June 29, 2021
    Assignee: Faron Pharmaceuticals Oy
    Inventors: Mikael Maksimow, Markku Jalkanen, Marita Vainio